Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)

Name: Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)
Creator: Andrew Blauvelt
Published: 2022-07-12T14:47:58.193Z
Keywords: Dermatology, Clinical Trial, Atopic Dermatitis

Blauvelt, Andrew; Langley, Richard; Lacour, Jean-Philippe; Wollenberg, Andreas; Toth, Darryl; Laquer, Vivian; Beissert, Stefan; Herranz, Pedro; Pink, Andrew; Peris, Ketty; Fangel, Stine; Gjerum, Le; Corriveau, Joshua; Saeki, Hidehisa; Warren, Richard; Simpson, Eric; Reich, Kristian

doi:10.17632/ms9xg8cb9g.1

Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)

Published: 12 July 2022| Version 1 | DOI: 10.17632/ms9xg8cb9g.1

Contributors:

Andrew Blauvelt, Richard Langley, Jean-Philippe Lacour, Andreas Wollenberg, Darryl Toth, Vivian Laquer, Stefan Beissert, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard Warren, Eric Simpson, Kristian Reich

Description

Supplementary Information to accompany and support the manuscript: Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.

Files

Institutions

LEO Pharma A/S

Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)

Description

Files

Institutions

Categories

Licence